Study of the Potential Association of Adipose Tissue GLP-1 Receptor with Obesity and Insulin Resistance
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The increase in glucagon-like peptide-1 (GLP-1) activity has emerged as a useful therapeutic tool for the treatment of type 2 diabetes mellitus. The actions of GLP-1 on β-cells and the nervous and digestive systems are well known. The action of this peptide in adipose tissue (AT), however, is still poorly defined. Furthermore, no relationship has been established between GLP-1 receptor (GLP-1R) in AT and obesity and insulin resistance (IR). We provide evidence for the presence of this receptor in AT and show that its mRNA and protein expressions are increased in visceral adipose depots from morbidly obese patients with a high degree of IR. Experiments with the 3T3-L1 cell line showed the lipolytic and lipogenic dose-dependent effect of GLP-1. Moreover, GLP-1 stimulated lipolysis in 3T3-L1 adipocytes in a receptor-dependent manner involving downstream adenylate cyclase/cAMP signaling. Our data also demonstrate that the expression of the GLP-1R in AT correlated positively with the homeostasis model assessment index in obese IR subjects. Furthermore, prospective studies carried out with patients that underwent biliopancreatic diversion surgery showed that subjects with high levels of GLP-1R expression in AT, which indicates a deficit of GLP-1 in this tissue, were those whose insulin sensitivity improved after surgery, suggesting the potential relationship between AT GLP-1R and insulin sensitivity amelioration in obese subjects. Altogether these results indicate that the GLP-1/GLP-1R system in AT represents another potential candidate for improving insulin sensitivity in obese patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Accordingly, numerous studies have shown that following glucose overload, IR and diabetes clearly exhibit a decrease in circulating GLP-1 [58,67].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“On the contrary, the functional classification of OB individuals based on the degree of IR revealed that, in the context of a very high degree of IR, GLP-1R in VAT depots was significantly up-regulated.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“It is interesting that these authors showed that mature adipocytes and stromal vascular fraction (SVF), which include mesenchymal stem cells (MSCs), preadipocytes, fibroblasts, vascular endothelial cells and a variety of immune cells like AT macrophages, expressed GLP-1R at both the mRNA and protein levels.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Since the 1990s, reports have indicated that isolated mouse and human adipocytes contain GLP1-R ([58], and references therein).”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [58]
In the citing paper
“Vendrell et al. [58] firstly reported that GLP-1R in human AT is likely correlated with the degree of IR and that there is a definite up-regulation of GLP-1R at the gene and protein levels in the visceral fat depot in individuals with morbid obesity (OB) and a high degree of IR.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [58]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Weyer, C., Foley, J. E., Bogardus, C., Tataranni, P. A., & Pratley, R. E. (2000) · Diabetologia · doi:10.1007/s001250051560 · Cited by 799
Weight Change and Diabetes Incidence: Findings from a National Cohort of US Adults
Ford, E. S., Williamson, D. F., & Liu, S. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009256 · Cited by 624
Gutzwiller, J.-P., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 521
Nielsen, L. L., Young, A. A., & Parkes, D. G. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.028 · Cited by 457
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“These recent studies include the finding of the receptor in differentiating mouse 3T3-L1 pre-adipocytes [382e384], adipocytes formed from human bone marrow-derived mesenchymal stem cells [385], human epicardial fat [386], and in human visceral white adipose tissue [387].”
BackgroundPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“GLP-1 (10–100 nM, 4 hr) increased lipolytic rates in human primary adipocytes in vitro (Vendrell et al., 2011).”
BackgroundTrends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
“For example, (1) Glucagon-like peptide 1 (GLP1) is an intestinal hormone that can enhance insulin secretion in a glucosedependent manner by activating the GLP-1 receptor (GLP-1R) that is highly expressed on islet β cells.(462,463) GLP-1 receptor agonists including Liraglutide, Semaglutide, Dulaglutide and Exenatide ha…”
BackgroundGlucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
“Interestingly, Vendell and colleagues reported that GLP-1R expression (mRNA, protein) is greatest in adipocytes isolated from patients with morbid obesity and in particular, IR [35].”
BackgroundRegulation of adipocyte lipolysis
Frühbeck, G., Méndez-Giménez, L., Fernández-Formoso, J.-A., Fernández, S., & Rodríguez, A. (2014) · Nutrition Research Reviews · doi:10.1017/s095442241400002x · Cited by 429
“A dose-dependent lipolytic effect of GLP-1 in 3T3-L1 adipocytes in a receptor-dependent manner involving downstream adenylate cyclase/cAMP signalling has been shown((83)).”
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
“confirmed the expression of GLP-1R in mature adipose cells by the detection of the mRNA and protein (58).”
BackgroundPleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“In various rodent models, administration of GLP-1R agonists induced BAT thermogenesis through increased uncoupling protein 1 (UCP1), mitochondrial respiratory chain element Cox4i1 (Cytochrome C Oxidase Subunit 4I1) and PGC1α, independent of nutrient intake, as well as altering the expression of transcription factors i…”
BackgroundLiraglutide causes large and rapid epicardial fat reduction
Iacobellis, G., Mohseni, M., Bianco, S. D., & Banga, P. K. (2017) · Obesity · doi:10.1002/oby.21718 · Cited by 251
“GLP-1 receptor (GLP-1R) is expressed in the adipose tissue and mRNA and protein expressions are increased in visceral fat (28,29).”
BackgroundPerivascular adipose tissue as a source of therapeutic targets and clinical biomarkers
Antoniades, C., Tousoulis, D., Vavlukis, M., Fleming, I., Duncker, D. J., Eringa, E., Manfrini, O., Antonopoulos, A. S., Oikonomou, E., Padró, T., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad484 · Cited by 224
“Glucagon-like peptide-1 (GLP-1) receptor expression levels in adipocytes are associated with insulin resistance, and GLP-1 receptor agonists promote the differentiation of adipocytes and restore adipocyte health in cell culture models.(62) In humans, the treatment of patients with obesity with the GLP-1 analogue lirag…”
BackgroundGonzález, N., Moreno-Villegas, Z., González-Bris, A., Egido, J., & Lorenzo, Ó. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0528-4 · Cited by 211
“GLP-1R at the VAT and subcutaneous stores was found elevated in obese and T2DM patients with insulin resistance, where it participated in the overexpression of adiponectin [117, 118].”
BackgroundThe Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
Packer, M. (2025) · JACC · doi:10.1016/j.jacc.2025.06.055 · Cited by 173
Iacobellis, G., & Villasante Fricke, A. C. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz042 · Cited by 168
“GLP-1 receptor is expressed in the adipose tissue and mRNA, and protein expressions are increased in epicardial and other visceral fat [18, 24, 28, 29].”
BackgroundGLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1
Xu, F., Lin, B., Zheng, X., Chen, Z., Cao, H., Xu, H., Liang, H., & Weng, J. (2016) · Diabetologia · doi:10.1007/s00125-016-3896-5 · Cited by 157
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects
Zhang, H., Sturchler, E., Zhu, J., Nieto, A., Cistrone, P. A., Xie, J., He, L., Yea, K., Jones, T., Turn, R., et al. (2015) · Nature Communications · doi:10.1038/ncomms9918 · Cited by 137
“Importantly, GLP-1R is expressed in adipose tissue, in both the stromal vascular and the adipocyte fraction and its expression level has been found to correlate with the degree of insulin resistance 46 .”
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
Bu, T., Sun, Z., Pan, Y., Deng, X., & Yuan, G. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0277 · Cited by 131
“Studies demonstrated that the fat-damaging effects of GLP-1 are effective for weight loss and may also improve insulin resistance in obese patients [95].”
BackgroundDozio, E., Vianello, E., Malavazos, A. E., Tacchini, L., Schmitz, G., Iacobellis, G., & Corsi Romanelli, M. M. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.04.039 · Cited by 118
Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance
Ceperuelo-Mallafré, V., Duran, X., Pachón, G., Roche, K., Garrido-Sánchez, L., Vilarrasa, N., Tinahones, F. J., Vicente, V., Pujol, J., Vendrell, J., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3350 · Cited by 112
“Analogous to other incretin receptors, such as GLP-1R (32), GIPR is largely expressed in cells from the SVF.”
BackgroundSantilli, F., Simeone, P. G., Guagnano, M. T., Leo, M., Maccarone, M. T., Di Castelnuovo, A., Sborgia, C., Bonadonna, R. C., Angelucci, E., Federico, V., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0589 · Cited by 114
“A GLP-1–specific receptor, structurally and/or functionally distinct from that expressed in the pancreas, has been identified in adipose tissue, and its mRNA and protein levels are increased in VAT from severely insulin-resistant, morbidly obese patients (25,26).”
BackgroundMartins, F. F., Marinho, T. S., Cardoso, L. E. M., Barbosa‐da‐Silva, S., Souza‐Mello, V., Aguila, M. B., & Mandarim‐de‐Lacerda, C. A. (2022) · Cell Biochemistry and Function · doi:10.1002/cbf.3751 · Cited by 112
“identified in sWAT, eWAT, preadipocytes in vitro, and differentiated adipocytes ex vivo.(10,49,50) Besides, liraglutide promoted proliferation and preadipocyte differentiation from primary cultures of adipocyte progenitors and in 3T3‐L1 lineage adipocytes.”
BackgroundHuman epicardial fat expresses glucagon-like peptide 1 and 2 receptors genes
Iacobellis, G., Camarena, V., Sant, D., & Wang, G. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-109563 · Cited by 112
“Moreover, recent experimental data suggest that glucagon-like peptide 2 (GLP-2) may produce beneficial effects on glucose metabolism in obese animal models [8, 9].”
BackgroundGiagulli, V. A., Carbone, M. D., Ramunni, M. I., Licchelli, B., De Pergola, G., Sabbà, C., Guastamacchia, E., & Triggiani, V. (2015) · Andrology · doi:10.1111/andr.12099 · Cited by 109
Wang, X.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14821 · Cited by 109
Epicardial fat: a new cardiovascular therapeutic target
Iacobellis, G. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.01.004 · Cited by 104
Outeiriño-Iglesias, V., Romaní-Pérez, M., González-Matías, L. C., Vigo, E., & Mallo, F. (2015) · Endocrinology · doi:10.1210/en.2014-1978 · Cited by 99
“Ex4 and GLP-1 have opposite effects on adipose tissue (6), where Ex4 mainly promotes lipolytic effects, whereas GLP-1 induces lipogenesis, at least in vitro (8).”
BackgroundModulation of Adipocyte Metabolism by Microbial Short-Chain Fatty Acids
May, K. S., & den Hartigh, L. J. (2021) · Nutrients · doi:10.3390/nu13103666 · Cited by 107
“However, a previous study showed that GLP-1 receptors were positively correlated with body weight and insulin resistance indices in subjects with morbid obesity [169].”
ResultLima-Martínez, M. M., Paoli, M., Rodney, M., Balladares, N., Contreras, M., D’Marco, L., & Iacobellis, G. (2016) · Endocrine · doi:10.1007/s12020-015-0710-y · Cited by 92
Kokkinos, A., Alexiadou, K., Liaskos, C., Argyrakopoulou, G., Balla, I., Tentolouris, N., Moyssakis, I., Katsilambros, N., Vafiadis, I., Alexandrou, A., et al. (2013) · Obesity Surgery · doi:10.1007/s11695-012-0743-8 · Cited by 90
“GLP-1 elevation is associated with improvement of insulin secretion and sensitivity [54, 55].”
BackgroundGLP-1 Improves Adipocyte Insulin Sensitivity Following Induction of Endoplasmic Reticulum Stress
Jiang, Y., Wang, Z., Ma, B., Fan, L., Yi, N., Lu, B., Wang, Q., & Liu, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01168 · Cited by 88
“GLP-1R Frontiers in Pharmacology | www.frontiersin.org 1 October 2018 | Volume 9 | Article 1168 was also found in adipocytes and the SVF of human visceral adipose tissues using RT-PCR and immunohistochemistry (Vendrell et al., 2011).”
MethodGupta, P., Bala, M., Gupta, S. K., Dua, A., Dabur, R., Injeti, E. R., & Mittal, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.029 · Cited by 101
Ghanim, H., Batra, M., Green, K., Abuaysheh, S., Hejna, J., Makdissi, A., Borowski, R., Kuhadiya, N. D., Chaudhuri, A., & Dandona, P. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14090 · Cited by 86
“proportion to the co-existent insulin resistance.(13) However, there are no previous data on the loss of body fat in association with the preservation of lean body mass following liraglutide in patients with T1DM.”
BackgroundLi, C.-J., Yu, Q., Yu, P., Yu, T.-L., Zhang, Q.-M., Lu, S., & Yu, D.-M. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-36 · Cited by 86
“9 mg once-daily achieved about 10% of body weight reduction after 6 months, the result was also much greater than those mainly done in Caucasians [13,29], however the Japanese study failed to observe the reductions in body fat tissue, and the present study using DXA and CT to assess the changes in liraglutide-induced…”
BackgroundResultInfluentialGlucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84
Characterization of the genetic architecture of infant and early childhood body mass index
Helgeland, Ø., Vaudel, M., Solé-Navais, P., Flatley, C. J., Juodakis, J., Bačelis, J., Koløen, I. L., Knudsen, G. P., Johansson, B. B., Magnus, P. M., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00549-1 · Cited by 91
Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes
El Bekay, R., Coín‐Aragüez, L., Fernández‐García, D., Oliva‐Olivera, W., Bernal‐López, R., Clemente‐Postigo, M., Delgado‐Lista, J., Diaz‐Ruiz, A., Guzman‐Ruiz, R., Vázquez‐Martínez, R., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13481 · Cited by 78
“Recently, we obtained evidence demonstrating the presence of the GLP-1 receptor in AT and showed that its mRNA and protein levels are increased in visceral AT (VAT) from morbidly obese (MO) patients with a high degree of insulin resistance (IR) (Montrose-Rafizadeh et al., 1997; Vendrell et al., 2011) and that, in 3T3-…”
BackgroundMethodResultDecara, J., Rivera, P., Arrabal, S., Vargas, A., Serrano, A., Pavón, F. J., Dieguez, C., Nogueiras, R., Rodríguez de Fonseca, F., & Suárez, J. (2018) · Acta Physiologica · doi:10.1111/apha.13008 · Cited by 76
“Glucagon-like peptide-1, a gut hormone that increases glucose-induced insulin release, is impaired in patients with type II diabetes mellitus and obesity.(11,12) The potential clinical relevance of the anti-diabetic properties of GLP-1R activation by the long-acting agonist liraglutide and its potential benefit in wei…”
BackgroundBays, H. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.029 · Cited by 73
Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes
Kato, H., Nagai, Y., Ohta, A., Tenjin, A., Nakamura, Y., Tsukiyama, H., Sasaki, Y., Fukuda, H., Ohshige, T., Terashima, Y., et al. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.008 · Cited by 70
“While GIP enhances insulin-induced lipogenesis and inhibits the lipolytic action of glucagon [26], GLP-1 directly stimulates lipolysis through activation of both cAMP-dependent protein kinase (PKA) and AMPK in fat cells [27,28].”
BackgroundThe Role of Gastrointestinal Hormones in Hepatic Lipid Metabolism
Mells, J., & Anania, F. (2013) · Seminars in Liver Disease · doi:10.1055/s-0033-1358527 · Cited by 70
“66 We and others have demonstrated that the GLP-1 receptor, initially cloned in the 1990s in the endocrine pancreas, is present on the hepatocyte.”
BackgroundHiguchi, N., Hira, T., Yamada, N., & Hara, H. (2013) · Endocrinology · doi:10.1210/en.2012-2275 · Cited by 72
“A GLP-1 receptor antagonist, exendin(9-39) (Ex9) (synthesized by Thermo Fisher Scientific K.”
BackgroundMethodSalvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Di Martino, A., Albanese, G., Colantuoni, S., Medicamento, G., et al. (2022) · Biomolecules · doi:10.3390/biom12020176 · Cited by 62
Body Fat Distribution, Diabetes Mellitus, and Cardiovascular Disease: an Update
Kang, P., & Neeland, I. J. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01969-5 · Cited by 69
“GLP-1 receptors are known to be expressed on adipose tissues (with upregulation on visceral adipocytes due to insulin resistance) [69, 70].”
Wu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 68
Iacobellis, G., & Baroni, M. G. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01687-1 · Cited by 56
Ohta, A., Kato, H., Ishii, S., Sasaki, Y., Nakamura, Y., Nakagawa, T., Nagai, Y., & Tanaka, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1363888 · Cited by 56
Direct effects of glucagon on glucose uptake and lipolysis in human adipocytes
Pereira, M. J., Thombare, K., Sarsenbayeva, A., Kamble, P. G., Almby, K., Lundqvist, M., & Eriksson, J. W. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110696 · Cited by 54
Ejarque, M., Guerrero-Pérez, F., de la Morena, N., Casajoana, A., Virgili, N., López-Urdiales, R., Maymó-Masip, E., Pujol Gebelli, J., Garcia Ruiz de Gordejuela, A., Perez-Maraver, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42770-1 · Cited by 53
Self-citationShimasaki, T., Masaki, T., Mitsutomi, K., Ueno, D., Gotoh, K., Chiba, S., Kakuma, T., & Yoshimatsu, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063626 · Cited by 52
“Studies performed in isolated adipocytes have demonstrated that GLP-1 has the ability to induce both lipogenic and lipolytic mechanisms in white adipose tissue (WAT) [7,8].”
BackgroundOpposite Regulation of Ghrelin and Glucagon-like Peptide-1 by Metabolite G-Protein-Coupled Receptors
Engelstoft, M. S., & Schwartz, T. W. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.07.001 · Cited by 61
Ceddia, R. P., & Collins, S. (2020) · Clinical Science · doi:10.1042/cs20190579 · Cited by 53
Turchini, G. M., Francis, D. S., Du, Z., Olsen, R. E., Ringø, E., & Tocher, D. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819587-1.00003-3 · Cited by 64
GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction
Pastel, E., McCulloch, L. J., Ward, R., Joshi, S., Gooding, K. M., Shore, A. C., & Kos, K. (2017) · Clinical Science · doi:10.1042/cs20160803 · Cited by 49
Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle
Amato, A., Baldassano, S., Liotta, R., Serio, R., & Mulè, F. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0525 · Cited by 48
“…brain and http://joe.endocrinology-journals.org 2014 Society for Endocrinology DOI: 10.1530/JOE-13-0525 Printed in Great Britain pancreas (Baggio & Drucker 2007, Tornehave et al. 2008), hepatic cells (Gupta et al. 2010), adipocytes (Vendrell et al. 2011), and gastric mucosa (Broide et al. 2013).”
BackgroundInfluentialUpdate on adipose tissue blood flow regulation
Sotorník, R., Brassard, P., Martin, E., Yale, P., Carpentier, A. C., & Ardilouze, J. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00351.2011 · Cited by 56
Decara, J., Arrabal, S., Beiroa, D., Rivera, P., Vargas, A., Serrano, A., Pavón, F. J., Ballesteros, J., Dieguez, C., Nogueiras, R., et al. (2016) · BioFactors · doi:10.1002/biof.1295 · Cited by 42
Ishii, S., Nagai, Y., Sada, Y., Fukuda, H., Nakamura, Y., Matsuba, R., Nakagawa, T., Kato, H., & Tanaka, Y. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3647 · Cited by 41
“As shown in Figures 1 and 2, FI, VFV, and IHL were all significantly decreased after 12 and 24 weeks of treatment.”
BackgroundInfluentialPetrovic, A., Igrec, D., Rozac, K., Bojanic, K., Kuna, L., Kolaric, T. O., Mihaljevic, V., Sikora, R., Smolic, R., Glasnovic, M., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45060288 · Cited by 41
Obesity-related insulin resistance: implications for the surgical patient
Tewari, N., Awad, S., Macdonald, I. A., & Lobo, D. N. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.100 · Cited by 42
GLP-1: benefits beyond pancreas
Muscogiuri, G., Cignarelli, A., Giorgino, F., Prodram, F., Santi, D., Tirabassi, G., Balercia, G., Modica, R., Faggiano, A., & Colao, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0137-y · Cited by 42
“or lipolytic activity when used at nanomolar doses [86–90].”
BackgroundCan We Decrease Epicardial and Pericardial Fat in Patients With Diabetes?
Muzurović, E. M., Vujošević, S., & Mikhailidis, D. P. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211006997 · Cited by 45
Liu, C., Hu, M., Zhang, M., Li, F., Li, J., Zhang, J., Li, Y., Guo, H., Xu, P., Liu, L., et al. (2014) · Metabolism · doi:10.1016/j.metabol.2014.06.015 · Cited by 38
“[2] Vendrell J, El Bekay R, Peral B, et al.”
BackgroundShao, N., Yu, X.-Y., Yu, Y.-M., Li, B.-W., Pan, J., Wu, W.-H., Zhang, H.-J., Ma, X.-F., Hao, M., & Kuang, H. (2018) · Andrologia · doi:10.1111/and.13039 · Cited by 27
“(Beiroa et al., 2014; Dickson et al., 2012; He et al., 2010; Shah & Vella, 2014; Tanaka et al., 2014; Vendrell et al., 2011; Yang et al., 2013).”
Zhu, R., & Chen, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1095432 · Cited by 42
“Frontiers in Endocrinology 13 from morbidly obese patients with a high degree of Insulin resistances (IR) (7).”
BackgroundTarsitano, M. G., Pandozzi, C., Muscogiuri, G., Sironi, S., Pujia, A., Lenzi, A., & Giannetta, E. (2022) · Nutrients · doi:10.3390/nu14142926 · Cited by 39
Chae, Y., Kim, T., Kim, M. K., Shin, C.-Y., Jung, I.-H., Sohn, Y. S., & Son, M.-H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144064 · Cited by 38
“GLP-1 receptors also exist on the surface of adipose tissue and their activation can cause adipogenesis [11] but enhance lipolysis [12].”
BackgroundOliveira, F. C. B., Bauer, E. J., Ribeiro, C. M., Pereira, S. A., Beserra, B. T. S., Wajner, S. M., Maia, A. L., Neves, F. A. R., Coelho, M. S., & Amato, A. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.803363 · Cited by 30
“It was previously reported that the lipolytic action of GLP-1 in 3T3-L1 adipocytes was accompanied by increased intracellular cAMP levels, implying that the classical receptor was activated by GLP-1 signaling in adipocytes (4).”
BackgroundVaittinen, M., Ilha, M., Herbers, E., Wagner, A., Virtanen, K. A., Pietiläinen, K. H., Pirinen, E., & Pihlajamäki, J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110635 · Cited by 33
Fernández‐García, J. C., Murri, M., Coín‐Aragüez, L., Alcaide, J., Bekay, R. E., & Tinahones, F. J. (2013) · Clinical Endocrinology · doi:10.1111/cen.12221 · Cited by 34
Zhang, N., Liu, C., Zhang, Y., Xu, D., Gui, L., Lu, Y., & Zhang, Q. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.02.065 · Cited by 30
Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats
Tanaka, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2653 · Cited by 28
Ahlkvist, L., Brown, K., & Åhrén, B. (2013) · Endocrine Connections · doi:10.1530/ec-12-0079 · Cited by 31
Huang, C., Wang, C., Yang, Y., Lin, C., & Peng, C. (2015) · Food & Function · doi:10.1039/c5fo00464k · Cited by 28
Li, X., Jiang, L., Yang, M., Wu, Y., Sun, S., & Sun, J. (2014) · Journal of Diabetes Research · doi:10.1155/2014/398518 · Cited by 30
“Studies have shown the presence of GLP-1 receptor in adipose tissue, and that the expression of GLP-1 receptor mRNA and protein was increased in visceral adipose depots from morbidly obese patients with a high degree of insulin resistance [24].”
BackgroundResultKullman, E. L., Kelly, K. R., Haus, J. M., Fealy, C. E., Scelsi, A. R., Pagadala, M. R., Flask, C. A., McCullough, A. J., & Kirwan, J. P. (2016) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00693.2015 · Cited by 30
The Functional State of Hormone-Sensitive Adenylyl Cyclase Signaling System in Diabetes Mellitus
Shpakov, A. O., & Derkach, K. V. (2013) · Journal of Signal Transduction · doi:10.1155/2013/594213 · Cited by 28
“In this connection, the assumption was put forward concerning alterations of the sensitivity of AC in the adipose tissue in T2DM to other activators of lipolysis, such as GLP-1, glucagon, and glucosedependent insulinotropic polypeptide-1 [160].”
BackgroundZhang, M., Liu, C., Hu, M., Zhang, J., Xu, P., Li, F., Zhong, Z., Liu, L., & Liu, X. (2015) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2015.03.001 · Cited by 26
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Zhou, Z., Yi, L., Popławska-Domaszewicz, K., Chaudhuri, К. R., Jankovic, J. J., & Tan, E. K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107770 · Cited by 35
Ben‐Shlomo, S., Zvibel, I., Varol, C., Spektor, L., Shlomai, A., Santo, E. M., Halpern, Z., Oren, R., & Fishman, S. (2013) · Obesity · doi:10.1002/oby.20340 · Cited by 28
“Furthermore, inhibition of GIP binding to its receptor using 1 lM of the GIP antagonist GIP (7-30) prevents the GIP-mediated increase in adiponectin levels (Figure 5A and 5B).”
BackgroundMethodInfluentialEffects of Exendin-4 on human adipose tissue inflammation and ECM remodelling
Pastel, E., Joshi, S., Knight, B., Liversedge, N., Ward, R., & Kos, K. (2016) · Nutrition & Diabetes · doi:10.1038/nutd.2016.44 · Cited by 25
Li, X., Jiang, L., Yang, M., Wu, Y., Sun, S., & Sun, J. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0156-8 · Cited by 24
“a high degree of insulin resistance [6], suggesting the possible important role of GLP-1 on adipose tissue.”
BackgroundWahl, S., Krug, S., Then, C., Kirchhofer, A., Kastenmüller, G., Brand, T., Skurk, T., Claussnitzer, M., Huth, C., Heier, M., et al. (2013) · Metabolomics · doi:10.1007/s11306-013-0586-x · Cited by 28
“Various in vitro studies have shown a stimulatory effect of GLP-1 and GIP on lipolysis in human and murine adipocytes (GettyKaushik et al. 2006; He et al. 2010; Ruiz-Grande et al. 1992; Sancho et al. 2005; Timper et al. 2013; Vendrell et al. 2011; Villanueva-Peñacarrillo et al. 2001).”
Hormonal Regulation of Lipogenesis
Gathercole, L., Morgan, S., & Tomlinson, J. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-407766-9.00001-8 · Cited by 31
Camastra, S., Astiarraga, B., Tura, A., Frascerra, S., Ciociaro, D., Mari, A., Gastaldelli, A., & Ferrannini, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12836 · Cited by 23
“In vitro studies documented a lipolytic effect of GLP-1 in isolated rat adipocytes(17) and 3T3-L1 adipocytes via cAMP signalling.(18) Exendin-4 has been reported to stimulate lipolysis in adipocytes from obese patients,(19) while GLP-1 has has been found to stimulate lipolysis in β-cells.”
BackgroundExercise and glucagon-like peptide-1: Does exercise potentiate the effect of treatment?
Hamasaki, H. (2018) · World Journal of Diabetes · doi:10.4239/wjd.v9.i8.138 · Cited by 29
Liraglutide improves lipid and carbohydrate metabolism of ovariectomized rats
Model, J. F. A., Lima, M. V., Ohlweiler, R., Vogt, É. L., Rocha, D. S., de Souza, S. K., Türck, P., Araújo, A. S. D. R., & Vinagre, A. S. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111158 · Cited by 24
Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis
Cignarelli, A., Giorgino, F., & Vettor, R. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2013.796996 · Cited by 24
“Studies performed in isolated rat and human adipocytes have demonstrated that GLP-1 may exert a dose-dependent dual action, with predominant lipogenic activity when used at picomolar concentrations or lipolytic activity when used at nanomolar doses (Perea et al., 1997; Ruiz-Grande et al., 1992; Sancho et al., 2005; Ve…”
BackgroundSubedi, L., Bamjan, A. D., Phuyal, S., Shim, J., Cho, S., Seo, J. B., Chang, K.-Y., Byun, Y., Kweon, S., & Park, J. W. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.039 · Cited by 22
Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln
Hasib, A., Ng, M. T., Khan, D., Gault, V. A., Flatt, P. R., & Irwin, N. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.027 · Cited by 20
Stafeev, I., Agareva, M. Y., Michurina, S. S., Tomilova, A., Shestakova, E. A., Zubkova, E., Sineokaya, M. S., Ratner, E. I., Menshikov, M. Y., Parfyonova, Y. V., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176476 · Cited by 23
Beaudry, J. L., & Drucker, D. J. (2019) · Endocrinology · doi:10.1210/endocr/bqz029 · Cited by 24
“GLP-1R expression within differentiated mouse 3T3-L1 pre-adipocytes (52) and in epicardial, and visceral WAT (53, 54).”
BackgroundInfluentialKupnicka, P., Król, M., Żychowska, J., Łagowski, R., Prajwos, E., Surówka, A., & Chlubek, D. (2024) · Pharmaceuticals · doi:10.3390/ph17111470 · Cited by 26
“In humans, GLP-1 receptors are found in the pancreas, gastrointestinal tract, heart, lungs, kidneys, brain, and adipose tissue [16–18].”
Li, Y., Liu, X., Li, G., & Zhang, P. (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00820-9 · Cited by 19
Xie, C., Alkhouri, N., & Elfeki, M. A. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.731 · Cited by 23
Lymperopoulos, A., Altsman, V. L., & Stoicovy, R. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157239 · Cited by 27
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
“Since the 1990s, reports have indicated that isolated mouse and human adipocytes contain GLP1-R ([58], and references therein).”
BackgroundInfluentialIdentification and characterization of adipose surface epitopes
Onogi, Y., Khalil, A., & Ussar, S. (2020) · Biochemical Journal · doi:10.1042/bcj20190462 · Cited by 16
Bingyan, C., Li, R., Huanhuan, T., Yanjia, M., Hu, X.-G., Jia, N., & Yueying, W. (2016) · 中医杂志:英文版 · doi:10.1016/s0254-6272(17)30013-4 · Cited by 17
Exercise in the Prevention and Treatment of Type 2 Diabetes
Kirwan, J. P., Heintz, E. C., Rebello, C. J., & Axelrod, C. L. (2023) · Wiley eBooks · doi:10.1002/cphy.c220009 · Cited by 26
Glucagon modulates proliferation and differentiation of human adipose precursors
Cantini, G., Trabucco, M., Franco, A. D., Mannucci, E., & Luconi, M. (2019) · Journal of Molecular Endocrinology · doi:10.1530/jme-19-0095 · Cited by 17
Metadata
- Authors
- Vendrell, J., El Bekay, R., Peral, B., García-Fuentes, E., Megia, A., Macias-Gonzalez, M., Real, J. F., Jimenez-Gomez, Y., Escoté, X., Pachón, G., Simó, R., Selva, D. M., Malagón, M. M., & Tinahones, F. J.
- Affiliations
- Instituto de Salud Carlos III (ES)
- University Hospital of Tarragona Joan XXIII (J.V., A.M., X.E., G.P.), IISPV, Rovira i Virgili University, Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, 43007 Tarragona, Spain
- Consejo Superior de Investigaciones Científicas (ES)
- Laboratorio de Investigación Biomédica (R.E.B., E.G.-F., M.G., Y.J.-G., F.J.T.), Hospital Virgen de la Victoria, 29010 Málaga, Spain
- Department of Cell Biology, Physiology, and Immunology (Y.J.-G., M.M.M.), Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CB06/03/0020) and Instituto de Salud Carlos III, Instituto de Investigación Biomédica, University of Córdoba, 14004 Córdoba, Spain
- Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (ES)
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2011-08-23
- Volume
- 152
- Issue
- 11
- Pages
- 4072-4079
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2143149722
- Cited by
- 173
- References
- 28
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 16 · 2023: 16 · 2022: 11 · 2021: 11 · 2020: 12 · 2019: 10 · 2018: 7 · 2017: 8 · 2016: 12 · 2015: 11 · 2014: 12 · 2013: 11 · 2012: 5
- FWCI
- 6.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, other-oa)
- Funders
- Ministerio de Ciencia e Innovación (SAF-2009-10461)
- Servicio Andaluz de Salud
- Instituto de Salud Carlos III (PS09/00997, PI070953)
- European Regional Development Fund
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- GLP-1 receptor, adipose tissue, obesity, insulin resistance, lipolysis, lipogenesis, 3T3-L1 adipocytes, biliopancreatic diversion, insulin sensitivity, visceral adipose tissue, type 2 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adipose Tissue, Animals, Cells, Cultured, Humans, Insulin Resistance, Obesity, Morbid, Prospective Studies, Adipocytes, Receptors, Glucagon, 3T3-L1 Cells, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.